Literature DB >> 10613828

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

M E Sharkey1, I Teo, T Greenough, N Sharova, K Luzuriaga, J L Sullivan, R P Bucy, L G Kostrikis, A Haase, C Veryard, R E Davaro, S H Cheeseman, J S Daly, C Bova, R T Ellison, B Mady, K K Lai, G Moyle, M Nelson, B Gazzard, S Shaunak, M Stevenson.   

Abstract

Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma viral RNA to levels below the limit of detection of available assays. However, even in patients whose plasma viral RNA levels have been suppressed to below detectable levels for up to 30 months, replication-competent virus can routinely be recovered from patient peripheral blood mononuclear cells and from semen. A reservoir of latently infected cells established early in infection may be involved in the maintenance of viral persistence despite highly active anti-retroviral therapy. However, whether virus replication persists in such patients is unknown. HIV-1 cDNA episomes are labile products of virus infection and indicative of recent infection events. Using episome-specific PCR, we demonstrate here ongoing virus replication in a large percentage of infected individuals on highly active anti-retroviral therapy, despite sustained undetectable levels of plasma viral RNA. The presence of a reservoir of 'covert' virus replication in patients on highly active anti-retroviral therapy has important implications for the clinical management of HIV-1-infected individuals and for the development of virus eradication strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613828      PMCID: PMC9513718          DOI: 10.1038/71569

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


  21 in total

1.  Correct integration of retroviral DNA in vitro.

Authors:  P O Brown; B Bowerman; H E Varmus; J M Bishop
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

2.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

3.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

4.  Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes.

Authors:  S Sonza; A Maerz; N Deacon; J Meanger; J Mills; S Crowe
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

5.  Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques.

Authors:  L Zhang; P J Dailey; T He; A Gettie; S Bonhoeffer; A S Perelson; D D Ho
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

6.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.

Authors:  H Zhang; G Dornadula; M Beumont; L Livornese; B Van Uitert; K Henning; R J Pomerantz
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

9.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.

Authors:  M I Bukrinsky; T L Stanwick; M P Dempsey; M Stevenson
Journal:  Science       Date:  1991-10-18       Impact factor: 63.714

View more
  154 in total

1.  Latency and viral persistence in HIV-1 infection.

Authors:  J D Siliciano; R F Siliciano
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 3.  Surrogacy in antiviral drug development.

Authors:  Sunil Shaunak; Donald S Davies
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 4.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

5.  Dynamics of HIV-1 recombination in its natural target cells.

Authors:  David N Levy; Grace M Aldrovandi; Olaf Kutsch; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

Review 6.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

7.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Persistence and dissemination of simian retrovirus type 2 DNA in relation to viremia, seroresponse, and experimental transmissibility in Macaca fascicularis.

Authors:  Roseanne C Wilkinson; Claire K Murrell; Rebecca Guy; Gail Davis; Joanna M Hall; David C North; Nicola J Rose; Neil Almond
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages.

Authors:  Steven P Zielske; Mario Stevenson
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 10.  Overcoming pharmacologic sanctuaries.

Authors:  Theodore J Cory; Timothy W Schacker; Mario Stevenson; Courtney V Fletcher
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.